HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC
Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.
Previous Post
STAT+: Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S.
Next Post
Women Reporting High HIV Stigma Had Higher Odds of Reduced Treatment Adherence
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago